Related by context. All words. (Click for frequent words.) 65 Prospective Randomized 65 TMC# C# 63 multicentre randomized 62 registrational Phase 62 REVIVE 62 PROTEGE 62 Phase Ib clinical 62 By JENNIFER LEARN 62 TRANSFORMS 62 EXCITE 61 PRECISE 61 STENT 61 INFORMATION SYSTEMS 61 Hsp# Inhibitor 61 ACCLAIM 61 RADIANT 61 VITALITY 61 Recurrent Glioblastoma 61 Multiple Ascending Dose 61 SERENE 61 Multicenter 60 Randomized Evaluation 60 PHASE III 60 DIAGNOSTIC 60 EURIDIS 60 phase IIa 60 multicenter phase 60 IN PATIENTS WITH 60 blinded randomized placebo controlled 60 MINDSET 60 Phase 1a clinical 60 IN NATURE 60 RE MODEL 60 By ERIC HJERSTEDT 60 Phase IIIb 60 STRATEGIC ALLIANCE 60 SORT OUT 60 HONORED WITH 60 multicenter Phase III 59 label multicenter Phase 59 APEX PD 59 Acute Ischemic Stroke 59 prospective multicenter 59 Elagolix 59 Resynchronization 59 relapsing multiple sclerosis 59 PHASE II 59 UNLOAD 59 Initiated Phase 59 REVIVE Diabetes 59 HYPERTENSION 59 PIXEL 59 HIGH PERFORMANCE 59 REVEAL 59 CLINICAL TRIAL 59 phase IIIb 59 multicenter prospective 59 STUDY OF 59 multicenter Phase II 59 multicenter multinational 59 TECHNOLOGY INC. 59 NO# [002] 59 ALLEGRO 59 Ranibizumab 59 Phase 1b clinical 59 placebo controlled clinical 59 Sapacitabine 59 Initiate Phase 59 THERAPEUTICS 59 NAVIGATOR 59 Acute Decompensated Heart Failure 58 Small Vessel 58 DESIGN AND 58 HOME THEATER 58 PROCESS FOR 58 DEPTH OF 58 Phase IIIb clinical 58 Study Evaluating 58 Medidur TM FA 58 ADMIRE HF 58 multicenter randomized placebo controlled 58 unique alkylating agent 58 BIOPHARMA 58 CERTIFICATION FOR 58 Randomized controlled 58 Adaptive Radiation Therapy 58 Prostate AdenoCarcinoma Treatment 58 Phase Ib Clinical Trial 58 treatment naive genotype 58 AND GLASS 58 TREATMENT OF 58 TM Everolimus Eluting 58 TMC# [002] 58 #mg QD [002] 58 multicentre randomized double 58 MAXIMA 58 FUNCTIONALITY 58 Phase III multicenter 58 prospective randomized multicenter 58 TECHNOLOGIST 58 COMPANION 58 PROJECTOR 58 Antiviral Therapy 58 placebo controlled Phase III 58 viral kinetics 58 Peginterferon 58 STEERING 58 Controlled Trial 58 randomized controlled Phase 58 double blinded placebo 58 Sorafenib HCC Assessment 58 MOTIVATE 58 MODULAR 58 CUSTOM 58 Pivotal Study 58 REFLEX 58 POTENT 58 TECHNICAL SUPPORT 58 LUX Lung 58 STAGE SET FOR 57 COMPONENT 57 Systemic Sclerosis 57 ONTARGET 57 II Clinical Trial 57 UPGRADE TO 57 Chronic Heart Failure 57 CHAMPION PCI 57 PREVAIL 57 TOPICAL 57 OF CHOICE 57 Drug Eluting Stent System 57 IMPLANT 57 Double Blind Placebo 57 REALISM 57 Prospective Multicenter 57 PARADIGM 57 NOW SHIPPING 57 Sirolimus eluting Coronary Stent 57 label multicenter 57 randomized Phase III 57 reslizumab 57 Trandolapril 57 TO AVOID PREGNANCY WHILE 57 CURRICULUM 57 multicenter randomized double 57 Dose Ranging Study 57 NSABP B 57 SENSORS 57 NEW WAY TO 57 Randomized Double Blind 57 CLARITY study 57 IIa clinical 57 COVERAGE FOR 57 Gastrointestinal Liner 57 Oral Fingolimod 57 TAUGHT ME 57 MIGRAINE 57 pharmacokinetic PK study 57 WELDING 57 Multicenter Phase 57 DYNA 57 SYSTEMS INC. 57 INTRODUCES THE 57 phase IIb clinical 57 Phase 1b trial 57 TO COMPETE 57 AND SCIENCE 57 prospective multicenter study 57 Endovascular System 57 Blinatumomab 57 Phase IIa trials 57 INSIGHT INTO 57 CANCER TREATMENT 57 DEVS 57 ZOSTAVAX 57 TOYOTA COROLLA 57 KRN# 57 Omacetaxine 57 CLO RP 57 ASTEROID 57 DIGITAL SIGNAGE 57 Phase III randomized 57 tolerability pharmacokinetics 57 ADVENT 57 double blinded randomized 57 placebo controlled Phase 57 EXCEED 57 LUMINATE 57 Multicenter Randomized Double 57 Pharmacokinetics PK 56 MARKETING DIRECTOR 56 azilsartan medoxomil 56 Severe Sepsis 56 FOR TREATMENT 56 plus Copegus R 56 MATCHED 56 CONFIRMED FOR 56 Hedgehog Pathway Inhibitor 56 AND SERVE 56 TECHNOLOGY FOR 56 EVOLUTION 56 DISTRIBUTION AGREEMENT WITH 56 STRATUS 56 fosbretabulin 56 Degarelix 56 ORENCIA ® 56 YOUR WAY TO 56 OKI ACCESS Technologies 56 RINGLING COLLEGE OF 56 EVALUATIONS 56 COMPETITION WINNERS 56 DA VINCI 56 WE WILL CONTINUE TO 56 OUTCOMES 56 BEST PRICE FOR EXCELLENT 56 CABERNET 56 investigational protease inhibitor 56 Phase #/#a 56 PEDIATRIC 56 CERVARIX 56 PHYSICAL THERAPY 56 ATTAIN 56 BENICAR 56 Tocilizumab 56 WINDOW OF 56 THYROID 56 GOUT 56 DermaVir Patch 56 XIENCE V Stent System 56 WAS NAMED 56 CELEBRATION OF THE 56 PRODUCT AND 56 EXPLORE 56 Diabetic Macular Edema 56 MEND CABG II 56 Phase IIA 56 CABANA 56 TUTORS 56 generation purine nucleoside 56 DO WELL 56 multicenter randomized controlled 56 Tanespimycin 56 OLYMPIA registry 56 ATTRACT 56 See CLINICAL PHARMACOLOGY 56 SECONDARY SCHOOL 56 biologic DMARD 56 MIST II 56 EVALUATION OF 56 INTERFACE 56 MADIT 56 Phase III randomized controlled 56 Myocardial Perfusion Imaging 56 CELEBRATING THE 56 randomized multicenter 56 Phase Ib II 56 CELLO 56 BREEDERS CROWN 56 TERADYNE 56 IN TERROR 56 TEAM LEADER 56 PRoFESS 56 DUROS 56 CIMZIA TM certolizumab pegol 56 CONQUER 56 refractory chronic lymphocytic 56 X RAY 56 PROGRESSION 56 PET FROM 56 BRIM2 56 Diabetic Macular Edema DME 56 PRACTICE AND 56 Interferon beta 1a 56 Pegylated Liposomal Doxorubicin 56 BENICAR HCT 56 REFRIGERATOR 56 TO HIGHLIGHT 56 INNOVATION AND 56 COPEGUS ribavirin 56 SHOW THEIR 56 PHOTOSHOP 56 AN EMERGING 56 multicenter Phase 56 Blind Placebo Controlled Trial 56 evaluating carfilzomib 56 CUTTING THE 56 FACTS ABOUT 56 INFORMATICS 56 phase IIb study 56 Randomized Phase II 56 PAUL Minn.MN 56 trastuzumab emtansine T DM1 56 FUEL CELLS 56 ENHANCEMENT 56 THERAPIES 56 FIBER OPTIC 56 PROCEDURE FOR 56 EDEMA3 56 CARDIAC 56 International Verapamil SR 56 DIGITAL PHOTOGRAPHY 56 controlled multicenter Phase 56 MATERIALS AND 56 NANOTECH 56 Lenalidomide 56 pioglitazone HCl 56 PROFILES OF 56 HOLS 56 patientswith 56 Phase 2b kidney transplant 56 FUEL CELL 56 STUDY RESULTS 56 somatostatin analog 56 prospective multicentre 56 AMCC QT# 56 rALLy clinical trial 56 NEVO TM 56 TAXUS ATLAS 56 SKIN CARE 56 PERSEUS clinical program 56 Randomised 56 SAFETY AND 56 novel VDA molecule 56 Intervention Trial 56 prospective multicenter randomized 56 Current Controlled Trials 56 ChronVac C R 56 ATRIUM 56 Randomized Phase 56 lexidronam injection 56 APPROXIMATE 56 ADAPTIVE 56 Microwave Ablation System 56 FOLFOX6 chemotherapy regimen 56 PHARM 56 FOR HEALTH 56 BOLDER 56 Intervention Effectiveness 56 evaluating tivozanib 56 Randomized Clinical Trial 56 VELCADE melphalan 55 REVLIMID lenalidomide 55 ILLUSTRATE 55 PROGRAM COORDINATOR 55 single ascending dose 55 TEST OF 55 lorcaserin Phase 55 Pharmacokinetic Study 55 phase IIb trial 55 Randomized Double Blind Placebo 55 dose escalation clinical 55 multicentre prospective 55 Clinical Trial Evaluating 55 Randomized Double blind 55 EXCELLENCE IN 55 Xeloda ® 55 SEARCH FOR THE 55 BIOMEDICAL 55 POLYMER 55 TASTE FOR 55 thorough QT 55 SLATED 55 HCV SPRINT 55 ADONIS 55 ALZHEIMER 'S DISEASE 55 CLOSE TO THE 55 huN# DM1 55 BE PART OF 55 INCUBATOR 55 PRELUDE 55 DU #b 55 INFORMATION SECURITY 55 Endovascular Valve Edge 55 INNOVATIONS 55 NAME FOR 55 multicenter randomized clinical 55 Dapagliflozin 55 oral ridaforolimus 55 hyperphenylalaninemia HPA due 55 IN ONTARIO 55 VICTOR E1 55 Sanofi Pasteur Fluzone 55 PLASMA 55 SOLAR SYSTEM 55 pegylated interferon alfa 2a 55 ENRICH 55 LONG LIFE 55 doxorubicin docetaxel 55 Phase #b/#a clinical 55 STRATEGY FOR 55 Canon REALiS 55 #:# randomization 55 plus COPEGUS 55 THIN FILM 55 Phase III Clinical Trial 55 HuMax CD#b 55 Bare Metal Stent 55 SPIRIT FIRST 55 SUFFERING FROM 55 ASSERT 55 ASSESSMENT OF 55 EXPLORE Xa 55 Left Ventricular Dysfunction 55 EXTENDING THE 55 ExTRACT TIMI 55 diarrhea predominant irritable 55 relapsed MM 55 Plicera 55 Combination REOLYSIN R 55 FLU SHOT 55 DAPT Study 55 Meets Primary Endpoint 55 INTRODUCES NEW 55 COST EFFECTIVE 55 Non Alcoholic Steatohepatitis 55 PSMA ADC 55 WHITNEY MUSEUM OF 55 Phase III psoriasis 55 celgosivir 55 TMC# r 55 Eluting Stent 55 nucleotide analog 55 ROCKET AF 55 ILLUMINATE 55 HORIZONS 55 YOUR DOCTOR 55 RE LY 55 substudy 55 SCH # 55 HEALTH SERVICES 55 cutaneous T 55 Schizophrenia Treatment 55 resminostat 55 Multicentre 55 PHOTOGRAPHIC 55 AUTHENTICATION 55 SEX ATTACK 55 ROBOTICS 55 pregabalin Lyrica 55 phase Ib 55 REMINYL ® 55 'S FINAL 55 COMBINE TO 55 Eluting Coronary Stent System 55 DIMENSIONS 55 YOUR BRAIN 55 DIALYSIS 55 Zenvia Phase III 55 treatment naïve genotype 55 GetGoal Phase III 55 Metabolic Efficiency 55 PERSONA 55 ascending dose study 55 phase IIa clinical 55 Phase Ib study 55 neovascular form 55 Safinamide 55 COMPARISON TO 55 PERSPECTIVES ON 55 EXPRESSION 55 mildly symptomatic 55 ANTI AGING 55 OPTIMUM 55 RESEARCH GROUP 55 Everolimus Eluting Coronary Stent 55 CECH 55 Scandinavian Simvastatin Survival 55 colesevelam HCl 55 INSPIRE Trial Phase III 55 RESOLUTE clinical 55 MEND CABG 55 Long Term Efficacy 55 OF EXCELLENCE 55 IMAGING 55 YOUR AGE 55 multicenter clinical 55 FOR EACH 55 DIPLOMA 55 pharmacodynamic PD 55 Cloretazine 55 WINTER SURVIVAL KIT 55 DATANG INTERNATIONAL POWER GENERATION 55 FOR HIMSELF 55 Phase 1b dose escalation 55 RAMP UP 55 Myocardial Infarction Study 55 Telmisartan 55 INITIATE 55 Ranolazine 55 DEB# 55 TREATMENT FOR 55 CARDIOLOGY 55 IMMUNIZATION 55 SALES CONSULTANT 55 SONGS OF 55 BEAUTY OF 55 ACCELERATE 55 evaluating mipomersen 55 CURRENT OASIS 7 55 evaluating REVLIMID 55 WASHER 55 FORD FUSION 55 randomized controlled multicenter 55 active comparator 55 GUIDE FOR 55 READY FOR NEW 55 MORTALITY 55 GATTEX ™ 55 RECORD1 55 Completes Enrollment 55 DESIGN CONTEST 55 MANAGEMENT SYSTEMS 55 INFECTIOUS DISEASE 55 NIPPON 55 UPGRADE FOR 55 PHASE OUT 54 GW# [003] 54 OFFERS NEW 54 TESTING AND 54 ENDURE 54 INTERPRETED 54 TASKi3 54 SPECIALIZED 54 Therapeutic Competitors Report 54 Bosutinib 54 prospective observational 54 ritonavir boosted 54 dirucotide MBP# 54 GARDASIL ® 54 AIM HIGH 54 ENESTnd 54 Subgroup Analysis 54 8mg/kg 54 TWO NEW 54 pain palliation 54 designated HVTN 54 COPERNICUS 54 ceftazidime 54 TURNING INTO 54 PROMUS R 54 Oral NKTR 54 STRENGTHENING THE 54 MASTER CHIEF 54 COLLABORATION 54 CAMELOT 54 LOOKS GREAT 54 BRIM3 54 Antimicrobial Coating 54 REGARDS 54 DOLLARS AND 54 Deadlinepix 54 Long Lesion 54 FUNCTIONING 54 multicentre randomized controlled 54 Phase IIB 54 APPLIANCE 54 HIGH COST OF 54 EID AL 54 serotonin norepinephrine reuptake inhibitor 54 Phase 2a Clinical Trial 54 FUJITSU 54 R roscovitine 54 Phase 2b 54 OF DISTINCTION 54 RESIST 54 FLU VACCINE 54 BY CHANCE 54 AIR CF1 54 Custom NX R 54 Aggressive Drug Evaluation 54 ABSTRACTS 54 rALLy 54 PREVENTION OF 54 ribavirin RBV 54 TQT 54 APTIVUS 54 EINSTEIN DVT 54 preclinical efficacy 54 LABORATORY 54 Valsartan 54 MOMENTS IN 54 TO BED 54 prospective randomized controlled 54 dosing cohorts 54 REQUEST FOR PROPOSALS 54 NATURE OF 54 HOW WAS THE 54 dual endothelin receptor antagonist 54 icatibant 54 RIVA D. 54 LAUNCHES ONLINE 54 ORGANISE 54 COMMERCIAL MANAGER 54 DOUBLE FOR 54 ACCOMPLISH 54 ADVANCE PD 54 CLINICAL 54 Phase III placebo controlled 54 CONTINUING EDUCATION 54 Observational Study 54 Lymphocytic 54 CO ORDINATOR 54 polymerase inhibitor 54 EQUIPPED 54 DOXIL 54 pharmacokinetics PK 54 pharmacokinetic pharmacodynamic 54 Placebo Controlled 54 alfa 2a 54 CERTIFICATION 54 HOW WELL 54 TEST FOR 54 PROWESS 54 CRUCIAL WIN 54 TRYING TO GET 54 ARCHITECTURAL 54 ENTERTAINMENT IN BRIEF 54 Tumor Response 54 Ozarelix 54 CRITICAL CARE 54 sorafenib Nexavar 54 IMPACTS 54 FIBROMYALGIA 54 VIBRANT 54 CCR5 receptor antagonist 54 Adalimumab 54 MODERNIZATION 54 CUP HOPES 54 TREATMENTS 54 PEGylated interferon 54 Zenvia ™ 54 ART CAMP 54 prospectively randomized 54 LAUNCHES IN 54 ACTEMRA TM 54 CYPHER SELECT TM 54 PERSEUS 54 EQUIP OB 54 Clinical Evaluation 54 AMBITION 54 Intravascular 54 HORMONE 54 Placebo Controlled Trial 54 ANCHOR trial 54 Hospital Acquired Pneumonia 54 Prospective Randomized Trial 54 ENVIRO 54 ACOUSTIC MUSIC 54 investigational oral 54 Elitek 54 EARNS TOP 54 REVEAL Registry 54 Anturol TM 54 RELIANT 54 WOMEN WITH 54 ARIXTRA R 54 BARACLUDE ® 54 DEFER 54 quadrivalent HPV vaccine 54 Decompensated Heart Failure 54 STEP INTO 54 multicenter randomized 54 Edge STudy 54 Phase 2a clinical 54 ADVANTAGE OF 54 Tolvaptan 54 SANTE 54 AND RECOMMENDATIONS 54 CLARITY TIMI 54 SERUM 54 ADVANCES IN 54 CHECKER 54 Temsirolimus 54 Pivotal Phase 54 OF AFRICA 54 FINANCIAL MANAGEMENT 54 liposomal formulation 54 STRATOS 54 LEGACY OF 54 ENABLE 54 QUADRANT 54 BLOSSOMS 54 Acute Coronary Syndromes ACS 54 SEMESTER 54 Vascugel ® 54 GENERATOR 54 melphalan prednisone 54 pharmacodynamic effects 54 Pivotal Trial 54 HONDA ACCORD 54 MORE GOALS 54 STABILIZATION 54 Twinrix 54 DUTY OF 54 ADVANCED TECHNOLOGY 54 Phase IIb Trial 54 confirmatory clinical 54 COLLAGE 54 GRAVITAS trial 54 AIR2 Trial 54 Xanafide 54 PALIS PALTZ PGAL ROSV 54 CARING FOR 54 syngo ® 54 THERAPEUTIC 54 OBJECTIVES 54 metastatic malignant 54 Lantiq XWAY 54 FOSSIL FUELS 54 KYOCERA 54 MOBILITY 54 ENDEAVOR 54 FDG PET imaging 54 V Everolimus Eluting Coronary 54 ORMD 54 cisplatin gemcitabine 54 ABSTRACT 54 FOR TEACHERS 54 CANCERS 54 Acute Heart Failure 54 Pemetrexed 54 BODY AND 54 THE ORLANDO FLA. 54 FRONT RUNNING 54 erlotinib Tarceva ® 54 TO PUT ON 54 NEVO RES 54 RE LY ® 54 CARE HF 54 INTERACTIVE ENTERTAINMENT 54 SoftScan ® 54 Androxal TM 54 SOLUTIONS INC. 54 pharmacokinetic PK profile 54 CUSTOM II 54 Ziprasidone 54 NCT# ClinicalTrials.gov 54 PRECISION 54 DRIVEN TO 54 Phase Ia 54 QLT# 54 ACTIVE IN 54 ThermoDox R 54 SUNPOWER 54 PLANNER 53 Ovarian PLCO Cancer 53 LIAISON 53 USER 'S 53 Phase 2a trial 53 MVA MUC1 IL2 53 Denufosol 53 RELOVAIR ™ 53 toenail onychomycosis 53 YOUR CONFIDENCE 53 Randomized Controlled 53 GIRLS TEAM 53 WEB DESIGN 53 SUCCEED trial 53 UNITED MOVE 53 Pivotal Phase III 53 randomized multicenter trial 53 COOKING FOR 53 FURNISHED 53 EVRA 53 TISSUE 53 SHOWCASING 53 Clinical Efficacy 53 prospective randomized placebo 53 DIGITAL CAMERAS 53 telaprevir dosed 53 TOOLS AND 53 GOING INTO THE 53 WILL GO AHEAD 53 ARCALYST ® rilonacept 53 PEGINTRON TM 53 MY MOUTH 53 EmbraceAC 53 REG2 53 trodusquemine 53 label dose escalation 53 Annamycin 53 Cardiotoxicity 53 STRATEGY FOR AN OPEN 53 EMBLEM 53 BE TRUE 53 TRAINING FOR 53 pharmacodynamic profile 53 Stent Coating 53 POUR IN 53 Optical Coherence Tomography 53 AMENDMENT TO THE 53 DREAMS OF 53 oral deforolimus 53 Rosuvastatin 53 XIENCE TM 53 VITAL WIN 53 GLORY FOR 53 Acute Myocardial Infarction 53 REMOTE CONTROL 53 Sirolimus eluting 53 STEM CELL 53 ADULT EDUCATION 53 multinational multicenter randomized 53 Fragment Library 53 STUDENT WINS 53 PROGRAMS AND 53 ENERGY SAVING 53 E2 CLO 53 Phase IIIb study 53 observational cohort study 53 VALVE 53 vidofludimus 53 CONSULT 53 RLY 53 SCHEME FOR 53 METROPOLITAN MUSEUM OF 53 RESEARCH CENTRE 53 Heart Failure Trial 53 Ophena TM 53 paclitaxel poliglumex 53 SEGMENTATION 53 GAMMAGARD 53 Podium Presentation 53 PROGRAMMES 53 Accelerated Partial Breast Irradiation 53 dextromethorphan quinidine 53 DISEASES 53 ExAblate R 53 leukemia AML 53 HITACHI 53 MEMORY OF 53 Epirubicin 53 HIGH QUALITY 53 ASSESS 53 MERLIN TIMI 53 MICROSCOPE 53 IMPACT IMmunotherapy 53 certolizumab 53 TRADITION OF 53 ABSORB clinical 53 pertuzumab 53 Cardio3KG 53 Investigational Treatment 53 trials RCTs 53 ART CLASSES 53 CASES IN 53 CAPELLA 53 NEEDS HELP 53 teriflunomide 53 ID NCT# 53 randomized blinded 53 EchoCRT 53 Phase III randomized placebo 53 OmniWave 53 ENGAGE 53 CONNECTION BETWEEN 53 ENTREPRENEURIAL 53 GOT INTO 53 INVENTION 53 Cutaneous T 53 TELINTRA 53 pivotal Phase III 53 PROMOTING THE 53 HGS# 53 SOLAR POWERED 53 COMMITTEE 'S 53 GATTEX ® 53 Ambulatory EHR ensures 53 JUST BE 53 Investigational eFlow 53 AQUATIC 53 Bronchiectasis 53 metastatic hormone refractory 53 INFORMATION MEETING 53 IS EVERYTHING 53 miconazole Lauriad ® 53 SUPPORT SERVICES 53 Phase IIa clinical 53 COMPUTER SCIENCE 53 LIFE SAVER 53 RAPID RESPONSE 53 GLIMPSE OF 53 PHAROS 53 SATISFACTORY 53 Novel Oral 53 CASH CRISIS 53 Mg Uk 53 IMPACT DCM 53 BiTE R 53 SEIZURE OF 53 ROOM WITH 53 HER NEW 53 Naive Patients 53 SPONSORSHIP DEAL 53 MOBILIZATION 53 ETHOS 53 SHAKES UP 53 EARLY CHILDHOOD 53 NORTH END 53 XYZAL R 53 THERAPEUTICS INC. 53 dose escalation phase 53 ABILITY TO 53 STAINED GLASS 53 FEMALE WAS 53 XIENCE V Everolimus Eluting 53 ASSURE 53 NEW FRIENDS 53 LOST HIS 53 SHADE OF 53 TEST YOUR 53 ENVIRONMENTAL PROTECTION AGENCY 53 PROMUS TM 53 candesartan cilexetil 53 TO ADVISE 53 LAUNCHES WEBSITE 53 RE SURGE 53 hepatitis C HCV 53 ug dose 53 Ablation System 53 interferon gamma 1b 53 WHAT DO YOU DO 53 CHAPTERS 53 GIFTS OF 53 beta2 agonist 53 GATEWAY TO 53 RETROSPECTIVE 53 eosinophilic asthma 53 PAY PER 53 Chemoradiation 53 CFTR corrector 53 Oral Glucose Tolerance 53 Clolar ® 53 PFO migraine 53 fludarabine cyclophosphamide 53 ZEST 53 Low Incidence 53 Tuberculosis Vaccine 53 Sipuleucel T 53 DEADLINE TO 53 AN APPOINTMENT 53 INSIGNIA 53 CLORETAZINE TM VNP#M 53 Zicam Cold Remedy RapidMelts 53 Phase III confirmatory 53 PUBLISHED IN 53 ImmunoCAP ® 53 HIGH HOPES FOR 53 CRESTRON 53 FUNCTIONAL 53 CURE FOR 53 SYNTAX 53 SCOPE OF 53 TASKi2 53 INCB# [001] 53 number NCT# ClinicalTrials.gov 53 Carotid Revascularization Endarterectomy vs. 53 randomized multicenter Phase III 53 Phase Ib 53 SHUN 53 neratinib 53 GOES SOLO 53 morphometric vertebral fractures 53 Patency 53 comparing XIENCE V 53 ORACLE MS 53 Primary endpoints 53 peginterferon alfa 2b 53 WOMEN ARTISTS 53 DDP# 53 Meta Analysis 53 CLEAN WATER 53 RoACTEMRA 53 tacrolimus ointment 53 STEPS TO 53 CONTENT AND 53 SUPPORT YOUR 53 PEDESTAL 53 oral rivaroxaban 53 PNP inhibitor 53 GRADUATES FROM 53 WORKS BY 53 CORD II 53 eluting stent 53 LOOKING FOR NEW 53 PAYMENTS TO 53 multicenter placebo controlled 53 PHASE ONE 53 Phase III Pivotal 53 Arimidex Tamoxifen Alone 53 BCIRG 53 Endarterectomy 53 CLL8 53 BORSA 53 virus HCV protease inhibitor 53 Phase III Clinical Trials 53 PROJECT MANAGEMENT 53 MENTORING 53 transcranial Doppler ultrasound